A Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Rheumatoid Arthritis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2019 Results assessing changes in bone turnover and bone mineral density in subjects with rheumatoid arhtritis on glucocorticoids treated with denosumab, after discontinuing denosumab for 12 months presented at the 20th Annual Congress of the European League Against Rheumatism.
14 Jun 2008 Results were presented at the Annual European Congress of Rheumatology meeting in 2008.
14 Jun 2008 Results were presented at the 2008 Annual European Congress of Rheumatology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com